Health-related quality of life and inflammatory markers in malignant pleural mesothelioma

[1] Vogelzang NJ(2003)Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2636-2644

[2] Rusthoven JJ(2006)Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso Support Care Cancer 14 11-21

[3] Symanowski J(2004)Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the european organization for research and treatment of cancer core quality of life questionnaire and lung cancer module J Clin Oncol 22 3172-3180

[4] Denham C(2008)The prognostic significance of patient-reported outcomes in cancer clinical trials J Clin Oncol 26 1355-1363

[5] Kaukel E(2009)Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials Lancet Oncol 10 865-871

[6] Ruffie P(2007)Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma J Clin Oncol 25 5770-5776

[7] Gatzemeier U(2003)Cytokine-induced sickness behavior Brain Behav Immun 17 S112-S118

[8] Boyer M(2004)Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity Eur J Pharmacol 500 399-411

[9] Emri S(2008)Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms Oncol Nurs Forum 35 916-920

[10] Manegold C(2008)Cytokines and their relationship to the symptoms and outcome of cancer Nat Rev Cancer 8 887-899

[1] Vogelzang NJ(2003)Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2636-2644

[2] Rusthoven JJ(2006)Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso Support Care Cancer 14 11-21

[3] Symanowski J(2004)Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the european organization for research and treatment of cancer core quality of life questionnaire and lung cancer module J Clin Oncol 22 3172-3180

[4] Denham C(2008)The prognostic significance of patient-reported outcomes in cancer clinical trials J Clin Oncol 26 1355-1363

[5] Kaukel E(2009)Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials Lancet Oncol 10 865-871

[6] Ruffie P(2007)Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma J Clin Oncol 25 5770-5776

[7] Gatzemeier U(2003)Cytokine-induced sickness behavior Brain Behav Immun 17 S112-S118

[8] Boyer M(2004)Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity Eur J Pharmacol 500 399-411

[9] Emri S(2008)Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms Oncol Nurs Forum 35 916-920

[10] Manegold C(2008)Cytokines and their relationship to the symptoms and outcome of cancer Nat Rev Cancer 8 887-899